The time from the patient’s collapse to the initiation of CPR decreased from 6.five minutes to 5.7 minutes , whereas the time to administration of the 1st shock did not change significantly . Consequently, the %age of persons who acquired and survived minimal neurologic impairment at one month increased from 10.6 percent in 2005 to 19.2 percent in 2007 . The %age of individuals who received a shock from a public-access AED improved from 1.2 percent in 2005 to 6.2 percent in 2007 . The mean age of these patients decreased during the period of the 3-yr study period from 66.6 years to 60.6 years , and the indicate period from collapse to the administration of the first initiation or shock of CPR decreased from 3.6 minutes to 2.9 minutes .The first trial was a double-blind, single ascending dose Phase Ia research in healthful volunteers, investigating the effect of six doses of AZP-531 versus placebo in a total of 44 volunteers. The next trial was a double-blind 14-day multiple ascending dose Stage Ib research that aimed to assess the effect of four dosages of AZP-531 pitched against a placebo in a total of 32 overweight or obese, healthy subjects otherwise. The primary findings were the following: Following repeated administration for 14 days AZP-531 was well tolerated at all doses tested Once-a-day subcutaneous administration resulted in 24 hour exposure to AZP-531 at the higher doses tested Reductions in blood sugar levels were observed in obese and obese subjects, particularly in people that have elevated post-prandial glucose levels at baseline.